Cytokines have been investigated for decades and many important cytokines are involved in human diseases, such as interleukin-1 and osteoarthritis[@b1][@b2]. In 1989, Mosmann and colleagues[@b3] first reported a cytokine named "cytokine synthesis inhibiting factor (CISF)", which was secreted by T helper 2 (Th2) clones and inhibited synthesis of interferon-γ (IFN-γ) in Th1 clones. The CISF is now known as interleukin-10 (IL-10).

IL-10 is a cytokine with potent anti-inflammatory activity[@b4], produced by macropahges, T helper 2 cells and B lymphocytes[@b5][@b6]. IL-10 is a multifunctional cytokine involved in both innate and adaptive immune response[@b4][@b6]. As an inflammatory cytokine, IL-10 participates in the development of various diseases, such as kidney disease[@b7], heart failure[@b8], chronic infection[@b9][@b10] and cancer[@b10]. Although IL-10 has been extensively studied, the exact role of IL-10 in cancer is still elusive, since evidence suggested that IL-10 could mediate both anticancer immune response and immune-mediated rejection of cancer[@b6].

The gene encoding IL-10 is located on chromosome 1 (1q31-1q32). Three single nucleotide polymorphisms (SNPs) have been confirmed in the promoter region of IL-10: -592C\>A (rs1800872), -819C\>T (rs1800871), and -1082A\>G (rs1800896). Previous studies have shown that the three polymorphisms could affect the expression of IL-10[@b11][@b12] and alter the susceptibility to digestive cancers[@b13][@b14][@b15]. In addition to the elusive role of IL-10 in cancer development, the relationship between functional polymorphisms in IL-10 promoter region and cancer risk is also mysterious. Several meta-analyses have been performed to evaluate the association between IL-10 polymorphisms and cancer risk[@b16][@b17]; however, the association between -1082A\>G polymorphism and digestive cancer has not been assessed. Thus, this meta-analysis was performed to investigate the association between 1082 polymorphism and digestive cancer and assess the influence of confounding factors.

Methods
=======

Searching strategy
------------------

This meta-analysis were conducted and reported in corresponding to the PRISMA guidelines of systematic reviews and meta-analyses (see [Supplementary Table S1](#s1){ref-type="supplementary-material"} online)[@b18]. Online databases of PubMed, EMBASE, and CNKI were searched. The following terms were used: "Interleukin-10" or "IL10", "polymorphisms, single nucleotide" or "SNPs" and "cancer" or " neoplasm". Both plain text and medical subheadings of above key words were used for searching. No limitation of origin, languages, or other items was placed. To identify additional studies, references of previous meta-analyses and reviews were also manually searched.

Inclusion criteria
------------------

Records identified from databases were first screened by titles and abstracts, and then full-text articles were further reviewed. Eligible studies were judged by the following criteria: (1) case-control studies; (2) investigating the association between IL-10 -1082A\>G polymorphism and digestive cancer risk; (3) available genotype distribution data. According to the inclusion criteria, 2 authors (LC and TW) extracted eligible studies independently. The two authors reached consensus on each records.

Data extraction
---------------

Name of first author, year of publication, country where the study was carried out, cancer type, ethnicity, the source of control, number of cases and controls, genotype frequency in cases and controls were collected from eligible studies. Ethnicity was simply classified as Asian, Caucasian, and Latino ([Table 1](#t1){ref-type="table"}). Included studies were defined as hospital-based (HB) and population-based (PB) according to the source of control. Sample size of eligible studies was classified as large (\>500) or small (\<500). All data were extracted by two authors (LC and TW) independently with a predesigned data-collection form. Two authors reached consensus on each item.

Quality assessment
------------------

"Methodological quality assessment scale" (the scale can be found as [Supplementary Table S2](#s1){ref-type="supplementary-material"} online), a quality scale modified form previous meta-analyses[@b19], was used to evaluate methodological quality of eligible studies. Briefly, the following items were assessed: the representativeness of cases, source of controls, ascertainment of relevant cancer, sample size, quality control of genotyping methods, and Hardy-Weinberg equilibrium (HWE). Quality scores ranged from 0 to 10 (0: the lowest; 10: the highest).

Statistical analysis
--------------------

Odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated to estimate the association strength between IL-10 -1082A\>G polymorphism and digestive cancer risk. Deviation from the Hardy--Weinberg equilibrium (HWE) among controls subjects was tested by a x^2^-test and a P\<0.05 was considered as significant disequilibrium. The pooled ORs were calculated for allele comparison (G vs. A), homozygote comparison (GG vs. AA), heterozygote comparison (GA vs. AA), and dominant models (GG/GA vs. AA, considering the dominant effect of the IL-10 -1082G allele). For some studies only combined genotype (GG/G) data was reported[@b20][@b21], thus, only dominant comparison models were conducted for these studies. Heterogeneity between studies were determined by chi-square based on Q test and the random-effects model was used when there was significant heterogeneity (P\<0.1); otherwise, the fixed-effects model was applied[@b22]. Sub-group analyses were conducted according to cancer types, ethnicities, source of control, HWE, and sample size. Sub-group analysis was not performed for those subgroups with less than 2 studies. When significant heterogeneity presented, meta-regression was performed to detect the source of heterogeneity. Egger\'s test and Begg\'s test were used to test publication bias, and a p \< 0.05 was significant[@b23]. Sensitivity analysis was performed to assess individual studies\' effect on the pooled results. All meta-analyses were calculated by STATA (version 10.0; Stata Corp, College Station, Texas USA). And all P values are two-side.

Results
=======

Overview of eligible studies
----------------------------

According to our searching strategy, 752 records were retrieved and screened. After primary screening, 38 full-text papers were retrieved for further assessment[@b13][@b14][@b15][@b20][@b21][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40][@b41][@b42][@b43][@b44][@b45][@b46][@b47][@b48][@b49][@b50][@b51][@b52][@b53][@b54][@b55][@b56]. The study reported by Zhou SZ et al was excluded for lacking of detail genotype distribution data[@b56]. In the studies reported by El-Omar EM[@b29], Guo W[@b32], and Savage SA[@b14], both gastric cancer and esophageal cancer were reported and the data were presented independently, and each kind of the cancer was treated as a separate study. Thus, 40 eligible studies were included in this meta-analysis[@b13][@b14][@b15][@b20][@b21][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40][@b41][@b42][@b43][@b44][@b45][@b46][@b47][@b48][@b49][@b50][@b51][@b52][@b53][@b54][@b55]. The process of study selection was shown in [Figure 1](#f1){ref-type="fig"}.

Of the 40 eligible studies, 7195 patients of digestive cancer and 11755 controls were enrolled. Baseline characteristics of those studies were shown in [Table 1](#t1){ref-type="table"}. Most studies were performed among Asian population (24 studies) and Caucasian population (11 studies).

Methodological quality of eligible studies was assessed by a quality scale reported by previous studies. Generally, quality of eligible studies was acceptable, with an average score of 7.3. Of 40 analyzed studies, 23 were hospital-based and 17 studies were population based. As for HWE, 24 studies were in agreement with HWE, 13 studies were in disagreement with HWE and it was unable to test in 3 studies[@b20][@b21][@b44] due to combined data ([Table 2](#t2){ref-type="table"}). Since no genotyping error was reported, all studies were included in quantitative synthesis, and stratified analysis was performed to assess the influence of disagreement of HWE.

Meta-analysis Results
---------------------

By pooling all eligible studies, compared with the wild -1082A allele, we found the variant IL-10 -1082G allele was associated with significantly increased risk of digestive cancer in all four comparison models (G vs. A: OR = 1.181, 95% CI: 1.057--1.319; Heterogeneity, P\<0.001; [Figure 2](#f2){ref-type="fig"} and [Figure 3](#f3){ref-type="fig"}; [Table 2](#t2){ref-type="table"}).

Further sub-group analyses were conducted to assess the effects of potential confounding factors. When stratified by cancer types, we found the variant G allele only increased risk of gastric cancer (G vs. A: OR = 1.281, 95% CI: 1.102--1.488; Heterogeneity, P\<0.001) but did not alter the risk of colorectal cancer (G vs. A: OR = 0.937, 95% CI: 0.805--1.090; Heterogeneity, P = 0.710), hepatocellular carcinoma (G vs. A: OR = 1.104, 95% CI: 0.797--1.530; Heterogeneity, P = 0.283) or esophageal cancer (G vs. A: OR = 0.982, 95% CI: 0.820--1.175; Heterogeneity, P = 0.591). As for ethnicities, significant association was only found among Asians (G vs. A: OR = 1.399, 95% CI: 1.188--1.646; Heterogeneity, P\<0.001), while the -1082 polymorphism did not alter digestive cancer risk in Caucasians (G vs. A: OR = 1.016, 95% CI: 0.930--1.111; Heterogeneity, P = 0.796). HWE also significantly affected the pooled analysis. In the sub-groups classified according to source of control and sample size, meta-analysis results were quite consistent.

Heterogeneity and publication bias
----------------------------------

Notably, significant heterogeneity was observed in most comparisons. Thus, meta-regression was performed to detect the source of heterogeneity. The results indicated that sample size (P\<0.001), HWE (P\<0.001), source of control (P\<0.001), and cancer types (P = 0.03) contributed heterogeneity, while ethnicity (P = 0.207) did not. Publication bias was detected by Egger\'s test and Begg\'s test, and no evidence of publication bias was found (P = 0.133 for Begg\'s test and P = 0.524 for Egger\'s test; [Figure 4](#f4){ref-type="fig"}). As shown in [Figures 2](#f2){ref-type="fig"},[3](#f3){ref-type="fig"},[4](#f4){ref-type="fig"}, the study reported by Alpizar-Alpizar W[@b24] was an outlier. Thus, sensitivity analysis was performed to assess individual study\'s effect by omitting one study each time. Sensitivity analysis revealed that the pooled results were not affected by the study by Alpizar-Alpizar W et al or any other studies (see [supplementary Figure S3](#s1){ref-type="supplementary-material"} online), indicating our results were stable and reliable.

Discussion
==========

In this meta-analysis, we identified 40 eligible studies, including 7195 cases and 11755 controls. By pooling all eligible studies, we found the variant IL-10 -1082G allele significantly increased the susceptibility to digestive cancer, especially to gastric cancer and among Asian population.

By pooling all eligible studies, we found the IL-10 -1082A\>G polymorphism was associated with significantly increased risk of digestive cancer in all comparison models. Then stratified analysis showed that the increased risk was mostly contributed by gastric cancer, since significant association was observed only in gastric cancer and ORs in the sub-groups of gastric cancer were similar with those in overall analysis. It has been proposed that inflammation is a risk factor of tumorigenesis[@b57]. In the process of chronic gastric inflammation, different types of cytokines are secreted by activated neutrophils and mononuclear cells and altered cytokine levels have been observed[@b36]. Thus, it is biological plausible that IL-10 polymorphism increased risk of gastric cancer. Sub-group analysis revealed that the IL-10 -1082A\>G polymorphism was only associated with gastric cancer and no association was found for other digestive cancers, indicating that the role of IL-10 varied among cancers.

During sub-group analysis for ethnicities, we found ethnicity significantly affect the association between IL-10 -1082A\>G polymorphism and digestive cancer risk. Since the variant -1082G allele was only associated with increased risk in Asian population and no significant association was found in Caucasian population. This ethnicity difference is common for meta-analysis and may be explained by different environmental exposure, life style, and genetic background. Of note, since the incidence of gastric cancer was higher in Asian population, most Asian studies were about gastric cancer (19 of 24 studies, as shown in [table 1](#t1){ref-type="table"}). The higher prevalence of gastric cancer in Asian population might be another explanation for the ethnicity difference.

In the process of statistical analysis, we found the study reported by Alpizar-Alpizar W[@b24] and colleagues was an outlier. This could be explained by ethnicity difference, since the study was conducted among Latinos. Additionally, the frequency of IL-10 -1082G allele was very low in Alpizar-Alpizar\'s study[@b24]. Specifically, the GG and GA genotype was not detected in cases while the GG was not detected in controls and only one participants carried the heterozygote GA genotype in controls (0% in cases and 1.14% in controls), which would led to relatively wide confidence intervals as shown in [Figure 2](#f2){ref-type="fig"} and [Figure 3](#f3){ref-type="fig"}. It should also be highlighted that this study was conducted in high-risk population, which might be also related with the low frequency of G allele.

In this meta-analysis, we included 40 studies with 18950 participants. The sample size was large enough to provide enough statistical power. Additionally, no publication bias was detected by Egger\'s test and Begg\'s test, suggesting our results were unbiased. On the other hand, limitation of this meta-analysis should also be also highlighted. Firstly, heterogeneity was significant in this meta-analysis. Due to the significant heterogeneity, we used random-effects model to calculate the pooled ORs, which could provide stable results. To identify the source of heterogeneity, meta-regression was conducted and revealed that sample size, HWE, source of control, and cancer types were the sources. And stratified analyses were also performed to evaluate the influence of these confounding factors. Secondly, individual data were missed and we could not assess the effects of other factors, like environmental factors, life habit, and family history.

In summary, in this meta-analysis of 40 studies and 18950 participants, we found the variant IL-10 -1082G allele significantly increased susceptibility to digestive cancer, especially for gastric cancer and in Asian population.
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###### Baseline Characteristics of Eligible Studies

  Author                Year   Cancer Type    Country     Ethnicity   Study Design   Sample Size   Cases   Controls   HWE
  -------------------- ------ ------------- ------------ ----------- -------------- ------------- ------- ---------- -----
  Alpízar-Alpízar W     2005       GC        Costa Rica    Latinos         PB           Small       45        44       Y
  Bai XL                2008       GC          China       Asians          HB           Small       104      111      NA
  Bouzgarrou N          2009       HCC        Tunisia      African         HB           Small       58       145       Y
  Cacev T               2008       CRC        Croatia     Caucasian        PB           Small       160      160       N
  Cozar JM              2007       CRC         Spain      Caucasian        HB           Small       96       176       Y
  Crivello A            2006       CRC         Italy      Caucasian        PB           Small       62       124       Y
  Crusius JB            2008       GC         European    Caucasian        PB           Large       235      1134      N
  El-Omar EM(EC)        2003       EC           USA         Mixed          PB           Small       161      210       Y
  El-Omar EM(GC)        2003       GC           USA         Mixed          PB           Large       314      210       Y
  Forte GI              2008       GC          Italy      Caucasian        HB           Small       42       185       N
  García-González MA    2007       GC          Spain      Caucasian        PB           Large       404      404       Y
  Guo W (EC)            2005       EC          China       Asians          PB           Large       203      443       N
  Guo W (GC)            2005       GC          China       Asians          PB           Large       152      443       N
  He B                  2012       GC          China       Asians          HB           Small       196      248       Y
  Heneghan MA           2003       HCC         China       Asians          HB           Small       98       175       Y
  Kamangar F            2006       GC         Finland     Caucasian        PB           Small       112      205       Y
  Kang JM               2009       GC          Korea       Asians          HB           Large       334      335       Y
  Kim J                 2012       GC          Korea       Asians          HB           Large       495      495       Y
  Ko KP                 2009       GC          Korea       Asians          PB           Small       80       336       Y
  Lee JY                2005       GC          Korea       Asians          HB           Small       122      120       Y
  Liu J                 2011       GC          China       Asians          HB           Small       234      243       N
  Lu W                  2005       GC          China       Asians          PB           Large       250      300       N
  Macarthur M           2005       CRC           UK       Caucasian        PB           Large       257      408       Y
  Migita K              2005       HCC         Japan       Asians          HB           Small       48       188       N
  Morgan DR             2006       GC         Honduras     Latinos         HB           Small       170      161       Y
  Nieters A             2005       HCC         China       Asians          HB           Small       249      250      NA
  Ognjanovic S          2009       HCC          USA       Caucasian        PB           Small       118      230      NA
  Pan XF                2013       GC          China       Asians          HB           Large       308      308       Y
  Savage SA (EC)        2004       EC          China       Asians          HB           Large       115      385       N
  Savage SA (GC)        2004       GC          China       Asians          HB           Small       84       385       N
  Scola L               2009       PC          Italy      Caucasian        PB           Small       48       131       Y
  Shin CM               2011       GC          Korea       Asians          HB           Large       632      237       Y
  Shin HD               2003       HCC         Korea       Asians          HB           Large       230      792       Y
  Sugimoto M            2007       GC          Japan       Asians          HB           Small       104      168       Y
  Wu MS                 2002       GC          China       Asians          HB           Small       150      220       Y
  Xiao H                2009       GC          China       Asians          HB           Large       220      624       Y
  Yin YQ                2012       GC          China       Asians          HB           Small       75        75       N
  Zambon CF             2005       GC          Italy      Caucasian        HB           Large       129      644       Y
  Zeng X                2012       GC          China       Asians          PB           Small       151      153       N
  Zhou Y                2011       GC          China       Asians          PB           Small       150      150       N

CRC: Colorectal Cancer; EC: Esophageal Cancer; GC: Gastric Cancer; HCC: Hepatocellular Carcinoma; PC: Pancreatic Cancer; HB: hospital-based; PB: population-based; Large: \>500 participants; Small: \<500 participants; HWE: Hardy-Weinberg equilibrium; Y: agreement with HWE; N: disagreement with HWE; NA: unable to estimate.

###### Meta-analysis Results

                    G vs. A                       GG vs. AA                       GA vs. AA   GGGA vs. AA                                                                                                                                                                                            
  ---------------- --------- --------------------------------------------------- ----------- ------------- --------------------------------------------------- --------- ---- --------------------------------------------------- --------- ---- --------------------------------------------------- ---------
  Overall             37      1.181 (1.057--1.319)[\*](#t2-fn1){ref-type="fn"}     \<0.001        33        1.305 (1.044--1.631) [\*](#t2-fn1){ref-type="fn"}   \<0.001   37   1.168 (1.015--1.344) [\*](#t2-fn1){ref-type="fn"}   \<0.001   40   1.153 (1.005--1.323) [\*](#t2-fn1){ref-type="fn"}   \<0.001
  Cancer Types                                                                                                                                                                                                                                                                                            
  CRC                  4                    0.937 (0.805--1.090)                    0.71           4                      0.873 (0.638--1.195)                   0.737    4                  0.914 (0.709--1.179)                   0.572    4                  0.903 (0.709--1.149)                   0.552
  EC                   3                    0.982 (0.820--1.175)                    0.591          3                      0.872 (0.559--1.361)                   0.864    3                  1.113 (0.850--1.456)                   0.761    3                  1.070 (0.825--1.387)                   0.656
  GC                  25      1.281 (1.102--1.488) [\*](#t2-fn1){ref-type="fn"}    \<0.001        22        1.575 (1.146--2.164) [\*](#t2-fn1){ref-type="fn"}   \<0.001   25   1.277 (1.067--1.527) [\*](#t2-fn1){ref-type="fn"}   \<0.001   26   1.275 (1.056--1.538) [\*](#t2-fn1){ref-type="fn"}   \<0.001
  HCC                  4                    1.104 (0.797--1.530)                    0.283          3                      1.355 (0.587--3.124)                   0.757    4                  1.022 (0.714--1.463)                   0.335    6                  0.912 (0.739--1.126)                   0.431
  Ethnicity                                                                                                                                                                                                                                                                                               
  Asian               22      1.399 (1.188--1.646) [\*](#t2-fn1){ref-type="fn"}    \<0.001        19        2.072 (1.446--2.971) [\*](#t2-fn1){ref-type="fn"}    0.068    22   1.397 (1.161--1.680) [\*](#t2-fn1){ref-type="fn"}   \<0.001   24   1.351 (1.108--1.649) [\*](#t2-fn1){ref-type="fn"}   \<0.001
  Caucasian           10                    1.016 (0.930--1.111)                    0.796         10                      1.055 (0.880--1.264)                   0.649    10                 0.973 (0.786--1.205)                   0.044    11                 1.010 (0.881--1.159)                   0.386
  Control Source                                                                                                                                                                                                                                                                                          
  PB                  16      1.151 (1.001--1.324) [\*](#t2-fn1){ref-type="fn"}    \<0.001        15                      1.336 (0.973--1.835)                  \<0.001   16                 1.118 (0.915--1.364)                   0.001    17                 1.153 (0.964--1.379)                   0.001
  HB                  21      1.212 (1.014--1.449) [\*](#t2-fn1){ref-type="fn"}    \<0.001        18                      1.246 (0.940--1.650)                   0.38     21                 1.216 (0.992--1.489)                  \<0.001   23                 1.153 (0.935--1.422)                  \<0.001
  Sample Size                                                                                                                                                                                                                                                                                             
  Small               22      1.151 (1.010--1.312) [\*](#t2-fn1){ref-type="fn"}     0.016         18        1.291 (1.010--1.649) [\*](#t2-fn1){ref-type="fn"}    0.191    22                 1.170 (0.973--1.406)                   0.026    25                 1.109 (0.927--1.327)                   0.001
  Large               15      1.214 (1.013--1.456) [\*](#t2-fn1){ref-type="fn"}    \<0.001        15                      1.388 (0.944--2.040)                  \<0.001   15                 1.164 (0.938--1.444)                  \<0.001   15                 1.208 (0.974--1.498)                  \<0.001
  HWE                                                                                                                                                                                                                                                                                                     
  YES                 24                    1.125 (0.982--1.288)                   \<0.001        20                      1.045 (0.871--1.253)                   0.412    24                 1.069 (0.896--1.275)                  \<0.001   24                 1.103 (0.931--1.308)                  \<0.001
  NO                  13      1.280 (1.063--1.541) [\*](#t2-fn1){ref-type="fn"}    \<0.001        13        1.553 (1.018--2.367) [\*](#t2-fn1){ref-type="fn"}   \<0.001   13   1.386 (1.121--1.714) [\*](#t2-fn1){ref-type="fn"}    0.04     13   1.428 (1.151--1.772) [\*](#t2-fn1){ref-type="fn"}    0.012

\*Significant association; OR: odds ratio; CI: confident intervals; CRC: Colorectal Cancer; EC: Esophageal Cancer; GC: Gastric Cancer; HCC: Hepatocellular Carcinoma; HB: hospital-based; PB: population-based; Large: \>500 participants; Small: \<500 participants; HWE: Hardy-Weinberg equilibrium; YES: agreement with HWE; NO: disagreement with HWE.
